Evofem Biosciences, Inc. (EVFM)
| Market Cap | 1.13M |
| Revenue (ttm) | 17.27M |
| Net Income (ttm) | -6.25M |
| Shares Out | 118.66M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,192 |
| Average Volume | 378,639 |
| Open | 0.0098 |
| Previous Close | 0.0095 |
| Day's Range | 0.0095 - 0.0100 |
| 52-Week Range | 0.0061 - 0.0150 |
| Beta | -0.98 |
| RSI | 50.29 |
| Earnings Date | Aug 14, 2025 |
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. The company’s commercial products include PHEXXI, a vaginal gel for the prevention of pregnancy; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California. [Read more]
Financial Performance
Financial StatementsNews
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives -- -- Ensures a broader range of contraceptive choices is available to women state-wide...
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
-- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly...
Evofem Biosciences GAAP EPS of -$0.02, revenue of $4.8M
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
-- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Beco...
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
SAN DIEGO , Aug. 5, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO, Saundra Pelletier , will be honored with the Trailblazing Female Founders Award at t...
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store
— Pharma 1 Will Place Launch Quantity Order for PHEXXI in July 2025 — — Commercial Launch in UAE Targeted for Q1 2026 — SAN DIEGO , June 23, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosci...
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment...
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
— Pharma 1 Targets Mid-2025 Regulatory Submission in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis — SAN DIEGO , May 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Bioscien...
Evofem Biosciences GAAP EPS of $0.00, revenue of $0.85M
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO , May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. "Quarterly fluct...
Evofem Biosciences to Present at Emerging Growth Conference
SAN DIEGO , April 14, 2025 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that members of its management team will present at the upcoming Emerging Growth Conference as follow...
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it h...
Evofem Reports Fourth Consecutive Year of Net Sales Growth
-- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage...
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech...
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO
-- Allowed Patent Extends SOLOSEC IP to 2040 with Broad Claims that are Orange Book-listable -- SAN DIEGO , Feb. 13, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that t...
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial...
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders...
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is rai...
Evofem Biosciences GAAP EPS of $0.00, revenue of $4.16M
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. co...
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
— Pharma 1 anticipates filing UAE regulatory submission for Phexxi as a hormone-free contraceptive in Q3 2024 — — UAE contraceptive drug market is projected to reach $185.1 million by 2030 — SAN DIE...
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC
MUMBAI, India and NAPLES, Fla. and SAN DIEGO , July 15, 2024 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today...
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases — — Hello Alpha partnership boosts awareness of and access to Phexxi for millions of...
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
-- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phe...